Issue 1 JANUARY 2019
The Veeda Newsletter
MERGER & ACQUISITION
Investors are excited about GlaxoSmithKline Plc’s (GSK) plan to split the firm into two entities—pharmaceuticals and consumer healthcare.
Read more: https://www.livemint.com/Money/XVEWDuE2v9R1cYPNrW4qTI/What-the-GSK-Pfizer-merger-means-for-their-Indian-units.html
The acquisition comes less than 2 months after the companies announced that they had entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan
Read more :https://www.centerforbiosimilars.com/news/fuji-pharma-acquires-42-stake-in-biosimilar-developer-alvotech
Taiwan's major biotech manufacturing service provider Mycenax Biotech plans to buy some new drug testing platforms and a small cell strain supplier primarily in the US and Japan in 2019.
Read more : https://www.thepharmaletter.com/in-brief/brief-taiwan-s-mycenax-looking-for-acquisitions-updates-on-biosimilar
Healthcare sector may see further consolidation in 2019
Healthcare sector may see further consolidation in 2019 with tightening of regulatory environment set to make it difficult for small players to stay afloat in a highly competitive market.
Read more at: http://economictimes.indiatimes.com/articleshow/67319829.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Indian drugmakers hit record year for M&A and deal values
Activity in the pharma sector is rife in India, with mergers and acquisition deal values doubling given
Read more : https://www.thepharmaletter.com/article/indian-drugmakers-hit-record-year-for-m-a-and-deal-values
